Mansi K. Aparnathi

Mansi K. Aparnathi

Auto-generated profile, based on publicly available information

Mansi K. Aparnathi

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Neoplasia
Verified
Journal Article
Open access
MAMansi K. Aparnathi
Mansi K. Aparnathi
SHSami Ul Haq
Sami Ul Haq
JSJonathan St-Germain
Jonathan St-Germain
KNKevin C.J. Nixon
Kevin C.J. Nixon
JWJoseph Walton
Joseph Walton
BLBenjamin H Lok
Benjamin H Lok
Small cell lung cancer (SCLC) is a highly aggressive form of cancer, commonly treated with DNA-damaging therapies such as chemotherapy and radiotherapy. Unfortunately, relapse occurs early and frequently, suggesting that epigenetic mechanisms may play a role in this aggressive behavior. Targeting these mechanisms during initial treatment could potentially enhance anti-cancer effects. This study investigated the combination of DNA-damaging treatments with a panel of Epigenetic Chemical Probes (EpiProbes). Among these, MS023, a PRMT inhibitor, showed the greatest synergy with cisplatin and etoposide across various SCLC cell lines. The cytotoxicity of MS023 was correlated with PRMT1 gene expression and protein levels. BioID analysis revealed that many PRMT1 interactors are involved in mRNA splicing. Mechanistic validation demonstrated that MS023 impaired RNA splicing, increased DNA:RNA hybrids, and caused DNA double-strand breaks (DSBs). When combined with ionizing radiation (IR), MS023 significantly increased DSBs, as indicated by γH2AX foci. Additionally, MS023 enhanced the effects of IR and the PARP inhibitor talazoparib, both in vitro and in vivo. Therefore, targeting PRMT1 in combination with DNA-damaging therapies presents a promising strategy to improve treatment outcomes for SCLC.

2 September 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
UPUjas A. Patel
Ujas A. Patel
MSMary Y. Shi
Mary Y. Shi
JKJalal M. Kazan
Jalal M. Kazan
KNKevin CJ Nixon
Kevin CJ Nixon
XRXiaozhuo Ran
Xiaozhuo Ran
BLBenjamin H Lok
Benjamin H Lok
Small cell lung cancer (SCLC) is an aggressive malignancy, with most patients presenting with prognostically poor extensive-stage disease. Limited progress in standard care stresses the urgent need for novel therapies. Radiotherapy offers some survival benefit for selected patients with SCLC but could be enhanced with radiosensitizers. In this study, we identify HDAC3 as a novel radiosensitizing target in SCLC using a CRISPR knockout screen and demonstrate its efficacy and mechanism. SBC5 cells were transduced with a custom EpiDrug single-guide RNA library and treated with ionizing radiation (IR) to identify radiosensitizing genes. HDAC3 emerged as a candidate and was validated through genetic knockdown and pharmacologic inhibition (RGFP966) in multiple SCLC cell lines. Both approaches enhanced radiosensitivity, as shown by cell viability (dose modification factor10 = 1.14–1.69) and clonogenic assays (dose modification factor10 = 1.16–1.41). We assessed changes in chromatin accessibility by assay for transposase-accessible chromatin using sequencing and IR-induced DNA damage and repair using γH2AX foci detection, double-strand break (DSB) repair assays, and immunoblotting of repair proteins. HDAC3-deficient cells exhibited increased chromatin accessibility, greater IR-induced DSBs, and impaired repair capacity, resulting in persistent DNA damage. This repair defect sensitized cells to PARP inhibitors, for which combining RGFP966 with olaparib or talazoparib produced additive to synergistic effects. In SCLC xenograft models, HDAC3 knockdown or RGFP966, combined with IR, achieved significant tumor growth inhibition. Collectively, we identified HDAC3 as a novel radiosensitizing target in SCLC. Its functional loss increased the generation and persistence of IR-induced DNA DSBs, effectively sensitizing SCLC cell lines and xenografts to IR, providing a potential radiosensitization strategy to treat SCLC.

2 January 2026
Verified
Other
Open access
UPUjas A. Patel
Ujas A. Patel
MSMary Y. Shi
Mary Y. Shi
JKJalal M. Kazan
Jalal M. Kazan
KNKevin CJ Nixon
Kevin CJ Nixon
XRXiaozhuo Ran
Xiaozhuo Ran
BLBenjamin H Lok
Benjamin H Lok
Detailed information on cell lines and their culture conditions used in this study.

2 January 2026
Verified
Other
Open access
UPUjas A. Patel
Ujas A. Patel
MSMary Y. Shi
Mary Y. Shi
JKJalal M. Kazan
Jalal M. Kazan
KNKevin CJ Nixon
Kevin CJ Nixon
XRXiaozhuo Ran
Xiaozhuo Ran
BLBenjamin H Lok
Benjamin H Lok
ShRNA sequences that were used to generate HDAC3 KD and the non-targeting control.

2 January 2026
Verified
Other
Open access
UPUjas A. Patel
Ujas A. Patel
MSMary Y. Shi
Mary Y. Shi
JKJalal M. Kazan
Jalal M. Kazan
KNKevin CJ Nixon
Kevin CJ Nixon
XRXiaozhuo Ran
Xiaozhuo Ran
BLBenjamin H Lok
Benjamin H Lok
Small cell lung cancer (SCLC) is an aggressive malignancy, with most patients presenting with prognostically poor extensive-stage disease. Limited progress in standard care stresses the urgent need for novel therapies. Radiotherapy offers some survival benefit for selected patients with SCLC but could be enhanced with radiosensitizers. In this study, we identify HDAC3 as a novel radiosensitizing target in SCLC using a CRISPR knockout screen and demonstrate its efficacy and mechanism. SBC5 cells were transduced with a custom EpiDrug single-guide RNA library and treated with ionizing radiation (IR) to identify radiosensitizing genes. HDAC3 emerged as a candidate and was validated through genetic knockdown and pharmacologic inhibition (RGFP966) in multiple SCLC cell lines. Both approaches enhanced radiosensitivity, as shown by cell viability (dose modification factor10 = 1.14–1.69) and clonogenic assays (dose modification factor10 = 1.16–1.41). We assessed changes in chromatin accessibility by assay for transposase-accessible chromatin using sequencing and IR-induced DNA damage and repair using γH2AX foci detection, double-strand break (DSB) repair assays, and immunoblotting of repair proteins. HDAC3-deficient cells exhibited increased chromatin accessibility, greater IR-induced DSBs, and impaired repair capacity, resulting in persistent DNA damage. This repair defect sensitized cells to PARP inhibitors, for which combining RGFP966 with olaparib or talazoparib produced additive to synergistic effects. In SCLC xenograft models, HDAC3 knockdown or RGFP966, combined with IR, achieved significant tumor growth inhibition. Collectively, we identified HDAC3 as a novel radiosensitizing target in SCLC. Its functional loss increased the generation and persistence of IR-induced DNA DSBs, effectively sensitizing SCLC cell lines and xenografts to IR, providing a potential radiosensitization strategy to treat SCLC.

2 January 2026
Verified
Other
Open access
UPUjas A. Patel
Ujas A. Patel
MSMary Y. Shi
Mary Y. Shi
JKJalal M. Kazan
Jalal M. Kazan
KNKevin CJ Nixon
Kevin CJ Nixon
XRXiaozhuo Ran
Xiaozhuo Ran
BLBenjamin H Lok
Benjamin H Lok
Cells with HDAC3 loss have increased generation and persistence of DNA DSBs.